MedTrace Logo

Impact of SARS-CoV-2 (COVID-19) Infection, Treated in Ambulatory Care, on Long-term Quality of Life in a Parisian Military Population

NCT04893070 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 173

Last updated 2022-10-17

No results posted yet for this study

Summary

In April 2020, a meta-analysis on the long-term sequelae of respiratory syndromes related to seasonal coronaviruses (SARS and MERS) showed a significant alteration in quality of life, with in particular a decrease in physical and emotional capacities and a deterioration of social life. An improvement of the quality of life is evidenced after 6 months but without reaching the level usually observed in healthy people. The impact of SARS-CoV-2 infection on quality of life can be explained by the persistence of pleomorphic symptoms in the medium to long term. In the military population, the majority of SARS-CoV-2 cases present minor to moderate forms of the disease. Military personnel have living conditions that differ from those of the general population, in particular because of their geographic mobility, which may be responsible for isolation from the family. This isolation can be regular (we speak of "geographical celibacy" when the soldier is posted in a geographical area far from the family unit) and/or occasional, during missions on the national territory or outside. This singularity justifies a study on the impact of SARS-CoV-2 (COVID-19) infection on the quality of life in this specific population.

Conditions

  • SARS-CoV2 Infection
  • Covid19

Interventions

OTHER

Questionnaires COVID+

* 1 questionnaire on COVID-19 symptomatology and quality of life 12 months after COVID-19 first symptoms * 1 questionnaire on quality of life 18 months after COVID-19 first symptoms

OTHER

Questionnaires COVID-

* 1 questionnaire on quality of life at enrollment * 1 questionnaire on quality of life 6 months after enrollment

Sponsors & Collaborators

  • Direction Centrale du Service de Santé des Armées

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-15
Primary Completion
2022-07-04
Completion
2022-07-04

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04893070 on ClinicalTrials.gov